Zhong Lun Law Firm and O’Melveny & Myers have advised Chinese drug development service provider Pharmaron on its $588 million Hong Kong initial public offering, with JunHe and Skadden, Arps, Slate, Meagher & Flom advising the joint sponsors.
According to a press release, Pharmaron, based in Beijing and founded in 2004, is a fully integrated pharmaceutical Research & Development platform serving China and overseas pharmaceutical companies, assisting on drug discovery, pre-clinical and early clinical-stage development, while also expanding capabilities downstream to late clinical-stage development and commercial manufacturing.
The Zhong Lun team was led by partners Hu Tingfeng and Wang Chuan; the OMM team was led by partners Portia Ku, Zhu Ke and Edwin Kwok; the JunHe team was led by partner Wang Yi, with assistance from partner Sun Xiaojia; and the Skadden team was led by partners Julie Gao and Paloma Wang.
The Joint Sponsors are Goldman Sachs, CLSA and Orient Capital.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
